Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Moderna by Year
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Net R&D cost-sharing expense ($M) ($M)
Merck Moderna: $375M in FY2025, up 4.7% from a year earlier.
Latest, FY2025
375
Period ended Dec 31, 2025
Change on a year earlier
+4.7%
358 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Net R&D cost-sharing expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 375 | +4.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 358 | +64.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 218 | -24.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 288 | – | Form 10-K (filed 2025-02-25) ↗ |
Cite this data
StockData. (2026). Merck Moderna ($M), annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-moderna-rd
See every metric in the Merck KPI table. Data updated Oct 26, 2026.